Group 1 - Assertio (ASRT) shares have increased by 28.9% over the past four weeks, closing at $11.78, with a mean price target of $38.94 indicating a potential upside of 230.6% [1] - The average price targets range from a low of $24.74 to a high of $45.00, with a standard deviation of $9.04, suggesting a significant potential increase from the current price level [2] - Analysts show strong agreement on ASRT's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for ASRT's current year earnings has increased by 6.6% over the last 30 days, indicating positive sentiment among analysts [12] - ASRT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Company Overview - ADC Therapeutics SA (ADCT) is a notable stock within the Medical group, which comprises 929 companies and holds the 10 position in the Zacks Sector Rank [2] - The Zacks Rank system focuses on earnings estimates and revisions to identify stocks with improving earnings outlooks, with ADC Therapeutics currently rated 2 (Buy) [3] Performance Analysis - Over the past three months, the Zacks Consensus Estimate for ADCT's full-year earnings has increased by 24.9%, indicating improved analyst sentiment and a more positive earnings outlook [4] - Year-to-date, ADC Therapeutics has returned 6.5%, outperforming the Medical sector's average return of 6% [4] - In comparison to its specific industry, Medical - Biomedical and Genetics, which has gained about 21.1% this year, ADCT is slightly underperforming [6] Industry Context - The Medical - Biomedical and Genetics industry includes 450 stocks and is currently ranked 88 in the Zacks Industry Rank [6] - Another stock, Assertio (ASRT), has significantly outperformed the sector with a year-to-date return of 29.3% and is rated 1 (Strong Buy) [5] - The Medical - Drugs industry, where Assertio belongs, has 141 stocks and has seen a modest increase of 2.9% this year [7]

Core Viewpoint - Assertio (ASRT) shows significant upside potential with a mean price target of $38.94, indicating a 249.9% increase from its current price of $11.13 [1] Price Targets and Analyst Consensus - The average price target consists of five estimates ranging from a low of $24.74 to a high of $45.00, with a standard deviation of $9.04, suggesting a high degree of variability among analysts [2] - The lowest estimate indicates a potential increase of 122.3%, while the most optimistic estimate suggests a 304.3% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ASRT's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 6.6%, with one estimate moving higher and no negative revisions [12] - ASRT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][7] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism, as they may not reliably indicate actual stock price movements [10]

Group 1 - Assertio (ASRT) is a stock that has gained about 14% year-to-date, outperforming the average gain of 7% in the Medical group [4] - Assertio is ranked 8 in the Zacks Sector Rank, which evaluates 932 companies within the Medical sector [2] - The Zacks Rank for Assertio is 1 (Strong Buy), indicating a positive earnings outlook with a 6.6% increase in the full-year earnings estimate over the past quarter [3] Group 2 - Assertio belongs to the Medical - Drugs industry, which has 141 stocks and is currently ranked 96 in the Zacks Industry Rank, with an average gain of 1.9% year-to-date [5] - Another outperforming stock in the Medical sector is Butterfly Network, Inc. (BFLY), which has returned 15.8% year-to-date and has a Zacks Rank of 2 (Buy) [4][5] - The Medical Info Systems industry, to which Butterfly Network belongs, has 42 stocks and is currently ranked 168, with a year-to-date gain of 2% [6]

Core Viewpoint - Assertio Holdings, Inc. has regained compliance with Nasdaq listing requirements, specifically the Minimum Bid Price Rule, as of January 12, 2026 [1] Group 1 - The company received confirmation from Nasdaq regarding its compliance status [1] - The Minimum Bid Price Rule requires the company's common stock to maintain a minimum bid price of $1.00 per share [1]

Core Viewpoint - Assertio Holdings, Inc. announced the publication of clinical trial results for Rolvedon® (eflapegrastim-xnst) in The Oncologist, highlighting its effectiveness in early-stage breast cancer patients when administered on the same day as TC chemotherapy [1]. Group 1 - The clinical trial focused on patients with early-stage breast cancer (ESBC) [1]. - Rolvedon demonstrated efficacy when given on the same day as TC chemotherapy, which includes Taxotere (docetaxel) and cyclophosphamide [1].

Core Viewpoint - Assertio Holdings, Inc. announced a one-for-fifteen reverse stock split, effective December 26, 2025, to adjust its issued and outstanding common stock [1] Group 1 - The reverse split will be implemented through a certificate of amendment filed on December 19 [1] - The reverse split will take effect at 12:01 a.m. Eastern Time on the specified date [1] - Following the reverse split, the company's common stock will begin trading [1]

Summary of Key Points Core Insights - Several healthcare and biotech stocks experienced significant gains in after-hours trading following earnings updates and guidance revisions Company Performance - **KalVista Pharmaceuticals Inc. (KALV)**: Stock rose 11.29% to $12.12 after reporting a third-quarter net loss of $49.5 million ($0.92 per share), compared to a loss of $39.1 million ($0.84 per share) in the same period last year. Net product revenue for the quarter was $13.7 million [1] - **Health Catalyst Inc. (HCAT)**: Stock advanced 13.24% to $3.23 after reporting a third-quarter net loss of $22.2 million ($0.32 per share), compared to a loss of $14.7 million ($0.24 per share) a year ago. Revenue declined to $76.3 million from $86.4 million. For Q4 2025, projected revenue is about $73.5 million with adjusted EBITDA of $13.4 million. Full-year expectations are $310 million in revenue and $41 million in adjusted EBITDA [2] - **Bio-Techne Corp. (TECH)**: Stock climbed 8.72% to $62.47. The company reported first-quarter GAAP EPS of $0.24, up from $0.21 last year, while adjusted EPS remained flat at $0.42. Revenue declined 1% year-over-year to $286.6 million [3] - **Assertio Holdings Inc. (ASRT)**: Stock gained 8.30% to $0.87 after reporting third-quarter GAAP net income of $11.4 million ($0.11 per share), compared to a loss of $2.9 million ($0.03 per share) last year. Adjusted EPS rose to $0.18 from $0.02. Net product sales reached $49.5 million, up from $28.7 million [4] - **Abeona Therapeutics Inc. (ABEO)**: Stock moved up 8.51% to $4.59. The company is scheduled to report third-quarter results on November 12, with analysts expecting a loss of $0.34 per share on revenue of $5.53 million [5]

Core Insights - HEXPOL is focusing on strategic direction, operational performance, and new financial targets during the Capital Markets Day in 2025 [1] - The agenda includes presentations on growth, M&A strategy, and detailed insights into business segments [2] Group 1: Strategic Direction - CEO Klas Dahlberg will discuss the next phase of growth and value creation for HEXPOL [2] - The company aims to provide in-depth insights into market characteristics and future growth opportunities [1] Group 2: M&A Strategy - Magnus Berglund will present the company's M&A strategy, indicating a focus on expansion through acquisitions [2] Group 3: Business Segments - Presentations will cover various business segments, starting with the rubber compound section by Ralph Wolkener, Carsten Ruter, and Ken Bloom [2] - Following a break, Jan Wikström will discuss thermoplastic compounding and engineered products [2] - The final presentation will be delivered by Deputy CEO and CFO Peter Rosen, likely focusing on financial aspects [2]

Financial Data and Key Metrics Changes - Assertio reported total product sales of $49.5 million for Q3 2025, up from $28.7 million in the prior year, primarily driven by the Rosedown two-quarter pull forward [13] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in the prior year, largely due to higher Rosedown sales [16] - GAAP net income for Q3 2025 was $11.4 million, compared to a loss of $3 million in the prior year [16] Business Line Data and Key Metrics Changes - Rosedown net product sales reached $38.6 million in Q3 2025, a substantial increase from $15 million in the same quarter last year, attributed to the pull forward of sales [7] - Synthesan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior year, driven by higher volume [8][13] - Indocin sales decreased to $4.8 million in Q3 2025 from $5.7 million in the prior year, reflecting impacts from generic competition [14] Market Data and Key Metrics Changes - Rosedown achieved a 43% market share in the clinic Medicare Part B segment in Q3 2025, reflecting strong demand and strategic distribution efforts [10] - The company experienced a 42% year-to-date demand growth for Rosedown compared to the same period in 2024 [10] Company Strategy and Development Direction - The company aims to maintain price stability and predictability for Rosedown while pursuing further demand and market share growth [12] - Assertio is currently reviewing and refining its strategies moving forward under new leadership, focusing on growth assets [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's potential to generate significant value for patients and shareholders, highlighting a solid balance sheet and core growth assets [6] - The company anticipates a temporary decline in cash flow due to the Rosedown sales transition but expects improvement in Q2 2026 [16] Other Important Information - Assertio has executed a long-term supply agreement with its API manufacturer, ensuring stable supply and pricing for Rosedown [11] - The company is tightening its 2025 guidance, expecting full-year product sales between $110 million and $112 million and adjusted EBITDA between $14 million and $16 million [17] Q&A Session Summary Question: Linkage between labeler code and ASP for Rosedown - Management clarified that the labeler code change is not tied to ASP and emphasized a strategy of price stability and predictability [20] Question: Comments on Indocin market performance - Management noted good market share and volume for Indocin despite competition, with some price favorability observed [21] Question: Optimizing Rosedown's promotional and reimbursement strategy - Management is currently reviewing all strategies and will provide updates as refinements are made [24] Question: Expectations for Synthesan sales acceleration - Management indicated that Synthesan is competing in a generic market with a focus on raising awareness and promoting its unique delivery mechanism [30]